Loading…
China SXT Pharmaceuticals, Inc. is projected to decline to $2.28 by 2027, a -11% move from its current price of $2.55. SXTC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.39 | $2.55 | $2.72 | -0.03% |
| Jul 14 | $2.33 | $2.55 | $2.79 | -0.05% |
| Jul 15 | $2.28 | $2.55 | $2.84 | -0.08% |
| Jul 16 | $2.24 | $2.55 | $2.89 | -0.11% |
| Jul 17 | $2.21 | $2.55 | $2.93 | -0.14% |
| Jul 18 | $2.18 | $2.55 | $2.97 | -0.16% |
| Jul 19 | $2.15 | $2.55 | $3.01 | -0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.15 | $2.55 | $3.01 | -0.19% |
| Week 2 | $2.00 | $2.54 | $3.22 | -0.38% |
| Week 3 | $1.90 | $2.54 | $3.39 | -0.57% |
| Week 4 | $1.81 | $2.53 | $3.54 | -0.76% |
| Week 5 | $1.74 | $2.53 | $3.67 | -0.95% |
| Week 6 | $1.67 | $2.52 | $3.80 | -1.13% |
| Week 7 | $1.62 | $2.52 | $3.92 | -1.32% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
China SXT Pharmaceuticals, Inc. is a healthcare company focused on traditional Chinese medicine pieces (TCMP) in China. It engages in the research, development, manufacture, marketing, and sale of TCMP products, including advanced, fine, and regular TCMP lines, and a range of raw medicinal materials such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang.
It markets its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands.
The company was incorporated in 2005 and is headquartered in Taizhou, China. Its customer base includes pharmaceutical companies, chain pharmacies, hospitals, and pharmaceutical distributors.
SXTC is currently trading at $2.45, with a market capitalization of $93.63M, and a ranking of 4139.
The 30-day price range spans $1.52 to $3.95, reflecting near-term volatility and opportunities.
Technical indicators point to a bullish tilt: RSI14 is 60, SMA50 is $1.93, and SMA200 is $92.48, suggesting recent upside momentum relative to near-term and long-term averages.
Support is at $1.44 and resistance at $2.57, framing the immediate risk/reward. The long-range forecast envisions upside growth through 2030–2050, with 2030 avg $2.55 and 2050 avg $7.31, and ROIs ranging from single-digit gains to substantial long-term upside (e.g., 3.9 in 2030 and 198.3 in 2050).
A major floor 58.6% below — a decisive break under it would weaken the trend.
The nearest floor, 43.5% below — buyers have tended to step in here.
Price is pressing into resistance (0.8% away) — a breakout level to watch.
A major ceiling 30.1% above — clearing it would confirm fresh momentum.
Key SXTC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SXTC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.50 | Buy | $2.50 | Buy |
| MA 10 | $2.40 | Buy | $2.44 | Buy |
| MA 20 | $2.38 | Buy | $2.31 | Buy |
| MA 50 | $1.97 | Buy | $3.69 | Sell |
| MA 100 | $1.98 | Buy | $21.06 | Sell |
| MA 200 | $85.31 | Sell | $69.14 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.78 | Neutral |
| Stoch RSI (14) | 69.17 | Neutral |
| CCI (20) | 93.24 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 2.82 | Buy |
| Bollinger %B (20,2) | 0.78 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 1.15 | Buy |
| Awesome (5,34) | 0.42 | Buy |
| Ultimate (7,14,28) | 74.78 | Sell |
| Momentum (10) | 0.20 | Buy |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 2.59 | Sell |
| ADX (14) | 20.18 | Buy |
| ATR (14) | 0.11 | Info |
The 30-day technical picture is largely bullish, with momentum leaning to the upside.
RSI14 is 60, indicating room before overbought conditions.
Key moving averages show SMA50 at $1.93 and SMA200 at $92.48, providing context for near-term price movement and longer-term trend alignment.
Near-term support sits at $1.44 and resistance at $2.57, with the 30-day range from $1.52 to $3.95 providing a sense of volatility and potential entry/exit points.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.30 | $2.55 | $3.09 | 0% | Neutral | |
| $1.65 | $2.28 | $3.40 | -11% | Neutral | |
| $1.50 | $2.19 | $3.48 | -14% | Neutral | |
| $1.25 | $1.94 | $3.23 | -24% | Bearish | |
| $1.66 | $2.68 | $4.66 | +5% | Neutral | |
| $1.79 | $3.02 | $5.43 | +18% | Neutral | |
| $1.73 | $3.05 | $5.64 | +19% | Neutral | |
| $1.83 | $3.37 | $6.41 | +32% | Bullish | |
| $1.36 | $2.61 | $5.09 | +2% | Neutral | |
| $1.24 | $2.46 | $4.91 | -4% | Neutral | |
| $1.71 | $3.79 | $8.32 | +49% | Bullish | |
| $3.40 | $7.56 | $17.38 | +196% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.30 | $2.55 | $3.05 | +0.00% |
| August 2026 | $1.98 | $2.40 | $3.02 | -6.06% |
| September 2026 | $2.03 | $2.49 | $3.20 | +3.85% |
| October 2026 | $2.03 | $2.52 | $3.31 | +1.48% |
| November 2026 | $1.88 | $2.36 | $3.14 | -6.57% |
| December 2026 | $1.81 | $2.30 | $3.09 | -2.66% |
Click any year to see its month-by-month SXTC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
China SXT Pharmaceuticals, Inc.'s 2026 outlook centres on $2.55, within a $1.30 to $3.09 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, SXTC could reach as high as $3.40, with a base case around $2.28 and support toward $1.65 — roughly -11% from $2.55. Price action looks broadly range-bound.
Expect SXTC to range from $1.50 to $3.48 through 2028. The $2.19 average target implies a -14% move from current prices. That is -4% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The SXTC price prediction for 2029 points to an average of $1.94 (low $1.25, high $3.23) — a potential decline of -24% on today's $2.55. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2030, SXTC is projected to trade between $1.66 and $4.66, averaging $2.68 — a potential gain of +5% from today's $2.55. That is up +39% on the projected 2029 average. A consolidation phase looks the most probable path here.
China SXT Pharmaceuticals, Inc.'s 2031 outlook centres on $3.02, within a $1.79 to $5.43 range. That is up +13% on the projected 2030 average. That marks a +18% change versus current levels. Price action looks broadly range-bound.
By 2032, SXTC could reach as high as $5.64, with a base case around $3.05 and support toward $1.73 — roughly +19% from $2.55. A consolidation phase looks the most probable path here.
Expect SXTC to range from $1.83 to $6.41 through 2033. The $3.37 average target implies a +32% move from current prices. That is up +11% on the projected 2032 average. Momentum favours further upside here.
The SXTC price prediction for 2034 points to an average of $2.61 (low $1.36, high $5.09) — a potential gain of +2% on today's $2.55. A consolidation phase looks the most probable path here.
In 2035, SXTC is projected to trade between $1.24 and $4.91, averaging $2.46 — a potential decline of -4% from today's $2.55. That is -6% versus the projected 2034 average. Price action looks broadly range-bound.
China SXT Pharmaceuticals, Inc.'s 2040 outlook centres on $3.79, within a $1.71 to $8.32 range. That is up +54% on the projected 2035 average. That marks a +49% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, SXTC could reach as high as $17.38, with a base case around $7.56 and support toward $3.40 — roughly +196% from $2.55. Momentum favours further upside here.
Investing $1,000 in SXTC today (≈ 392.156863 SXTC) could be worth
$2,963.56
+$1,963.56 (+196%) by 2050 · US Dollar
Based on the average projected SXTC price of $7.56 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SXTCwould be worth at today's price.
$1,000 invested in SXTC on Jul 10, 2025 (≈ 3.898635 SXTC) would be worth
$9.94
-$990.06 (-99.0%) today · 0.01× · US Dollar
Based on a SXTC entry price of $256.5 vs. today's $2.55.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.45 | $1,040.82 | +4.1% |
| 1 month ago | $1.76 | $1,448.86 | +44.9% |
| 3 months ago | $2.32 | $1,099.14 | +9.9% |
| 6 months ago | $21.3 | $119.72 | -88.0% |
| 1 year ago | $256.5 | $9.94 | -99.0% |
| All time (5.0y) ago | $5,250 | $0.49 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SXTC forecast.
Our base-case forecast reaches $5.10 around 2050.
Implied market cap at $5.10: $194.91M
The multi-year forecast outlines a period of growth extending into the 2030s and beyond. In 2030, the average price is projected to be $2.55 with a ROI of 3.9 and a Neutral sentiment.
From 2031 to 2033, the forecast shows continued upside potential: 2031 avg $2.87, ROI 16.9; 2032 avg $2.96, ROI 20.8; 2033 avg $3.20, ROI 30.4, with increasing bullish sentiment.
By 2040, the average is forecast at $3.55 with a ROI of 45 and a bullish stance, culminating in 2050 with an average of $7.31 and a ROI of 198.3, supported by bullish sentiment.
The forecast also notes years with negative ROI in the near-term (e.g., 2027 ROI -11, 2028 ROI -15.2, 2029 ROI -23, 2034 ROI -0.8, 2035 ROI -2.4), reflecting a mix of volatility and risk along the path to longer-term upside.
Tap a question to reveal the answer.
Avg $2.55; min $1.57; max $4.42; ROI 3.9; sentiment Neutral.
The forecast shows mixed results with negative ROI in 2027 ( -11 ), 2028 ( -15.2 ), and 2029 ( -23 ), but positive momentum later, including an Avg of $7.31 in 2050 and ROI 198.3 with a Bullish outlook.
Yes—the 2050 max price is $16.81.
Current price $2.45; Market cap $93.63M.
30-day range: $1.52 to $3.95. RSI14 is 60; sentiment is BULLISH. SMA50 is $1.93 and SMA200 is $92.48; support is $1.44 and resistance is $2.57.
China SXT Pharmaceuticals, Inc. Community Discussion
0Share your China SXT Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.